PDSB - PDS Biotechnology Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0200
+0.0300 (+1.51%)
At close: 4:00PM EDT

2.0400 +0.02 (0.99%)
After hours: 6:56PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.9900
Open1.9700
Bid1.9800 x 800
Ask2.0400 x 800
Day's Range1.9100 - 2.0900
52 Week Range0.6150 - 6.7100
Volume357,820
Avg. Volume1,730,635
Market Cap31.03M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.7380
Earnings DateMay 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.48
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of Cancer

    PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the publication of data generated by the National Cancer Institute (NCI) based on preclinical studies of PDS Biotech’s lead clinical program, PDS0101, in combination with two other investigational anti-cancer agents. The article “Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine” by Rumfield et al. was published in the Journal for ImmunoTherapy of Cancer, and provides strong rationale for clinical evaluation of this three-component treatment combination in a recently initiated NCI-led Phase 2 clinical trial.

  • GlobeNewswire

    PDS Biotechnology and Farmacore Biotechnology Announce Co-Development of PDS0204 COVID-19 Vaccine

    PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced a co-development agreement with Farmacore Biotechnology for Versamune®-CoV-2FC, a Versamune®-based vaccine aimed at preventing COVID-19 infection. Under the collaboration, PDS Biotech and Farmacore will accelerate development of Versamune®-CoV-2FC into Phase 1 clinical testing in Brazil, with initial financial support provided by the Brazilian Ministry of Science, Technology, Innovation and Communication (MCTIC). Versamune®-CoV-2FC combines a Farmacore-developed recombinant SARS-CoV-2 protein with PDS Biotech’s Versamune® platform nanotechnology.

  • GlobeNewswire

    PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute

    PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the first patient has been dosed in the National Cancer Institute’s (NCI) Phase 2 clinical study of PDS0101 in the treatment of advanced human papillomavirus (HPV) associated cancers. This clinical trial involves a combination of PDS0101 with two clinical development-stage immune-modulating agents, Bintrafusp alfa (M7824) and NHS-IL12. The NCI Center for Cancer Research’s Genitourinary Malignancies Branch (GMB) and Laboratory of Tumor Immunology and Biology (LTIB) are jointly leading this Phase 2 trial evaluating PDS0101, which combines the Versamune® platform with targeted antigens in HPV-expressing cancers, in combination with Bintrafusp alfa (M7824) and NHS-IL12.

  • Wall Street Suggests Buying These 2 Falling Knives
    GuruFocus.com

    Wall Street Suggests Buying These 2 Falling Knives

    Their share prices are predicted to bounce back strongly Continue reading...

  • The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid
    Benzinga

    The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * argenx SE - ADR (NASDAQ: ARGX) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Imara Inc (NASDAQ: IMRA) * Inari Medical Inc (NASDAQ: NARI) * Intellia Therapeutics Inc (NASDAQ: NTLA) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Passage Bio Inc (NASDAQ: PASG) * Qiagen NV (NYSE: QGEN) * Replimune Group Inc (NASDAQ: REPL) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 4) * Evofem Biosciences Inc (NASDAQ: EVFM)(priced its 28.5 million common stock offering) * Iterum Therapeutics PLC (NASDAQ: ITRM)Stocks In Focus Adamas' Regulatory Application For Label Expansion For Parkinson's Drug Accepted For Review Adamas Pharmaceuticals Inc (NASDAQ: ADMS) said the FDA has accepted its sNDA for Gocovri as a treatment for OFF episodes in Parkinson's disease patients receiving levodopa-based therapy. The company said the anticipated PDUFA action date is Feb. 1, 2021.Gocovri has already been approved for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.The stock rallied 18.56% to $3.13 in after-hours trading.Oxford Immunotech Approached With $400M Bid Medical diagnostics company Oxford Immunotec Global PLC (NASDAQ: OXFD) is being approached with a $15 per share or a $400 million offer by a consortium of private equity investors led by KKR and Ampersand Capital Partners, Reuters reported.The company had apparently approached several health care peers in the past year but was unsuccessful in striking a deal.The stock climbed 15.74% to $15 in after-hours trading.Related Link: Attention Biotech Investors: Mark Your Calendar For June PDUFA DatesAbbVie Forges Partnerships With 3 Institutions For Developing COVID-19 Antibody Treatment AbbVie Inc (NYSE: ABBV) announced a collaboration with Harbour BioMed, Utrecht University and Erasmus Medical Center to develop a novel antibody therapeutics to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus.The collaboration plans to study the fully human, neutralizing antibody 47D11 discovered by institutions that targets the conserved domain of the spike protein of SARS-CoV-2.AbbVie will support preclinical activities, while also preparing for later stage preclinical and clinical development work. The company has received an exclusive option for licensing the candidate.Merck Gets FDA Approval For Triple-combo Antibiotic To Treat Hospital-Acquired Pneumonia Merck & Co., Inc. (NYSE: MRK) announced FDA approval of its Recarbrio - a triplet combination of imipenem-cilastatin and relebactam - to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients 18 years of age and older.Novartis Announces Positive Results For Asthma Study Novartis AG (NYSE: NVS) announced publication of full results from the Phase 3b ARGON study in Respiratory Medicine, which showed once-daily treatment with single inhaler, high- and medium-dose Enerzair Breezhaler demonstrated non-inferiority to a free combination of twice-daily, high-dose salmeterol xinafoate/fluticasone propionate, plus once-daily tiotropium, delivered in two different devices, in improving quality of life in people with uncontrolled asthma.Among secondary analyses, improvements in lung function, asthma control, health status, and reductions in moderate exacerbations were observed with high-dose once-daily IND/GLY/MF compared to high-dose Sal/Flu plus Tio, the company said.PDS Biotech To Evaluate Lead Asset In Mid-Stage Study In Cervical Cancer PDS Biotechnology Corp (NASDAQ: PDSB) announced a Phase 2 clinical trial to evaluate its lead immunotherapy product, PDS0101, in combination with standard of care chemoradiotherapy for treatment of locally advanced cervical cancer.PDS101, according to the company, is being developed for multiple cancers associated with HPV infection, including anal, cervical and head and neck cancers. Results of a Phase 1 trial released in Sept. 2019 showed the investigational asset demonstrated potent in vivo induction of active killer T-cells that target cancer cells containing the cancer-causing HPV proteins, as well as an excellent safety profile with no limiting toxicities.Offerings Menlo Therapeutics Inc (NASDAQ: MNLO) said it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offeringThe stock slipped 14.03% to $1.90 in after-hours trading.On The Radar IPOs Applied Molecular Transport, a clinical-stage biopharma, priced its upsized initial public offering, or IPO, of 11 million shares at $14 per share compared to the initially estimated range of $12-$14. The shares will begin trading on the Nasdaq under the ticker symbol AMTI.Stockholm, Sweden-based specialty pharma company Calliditas Therapeutics priced its IPO of 9.231 million shares, consisting of a public offering of 8.317 million ADSs, with each ADSs representing two common shares, and a concurrent private placement of 924,000 common shares to certain qualified investors in Europe and certain other jurisdictions outside of the U.S. The company expects to raise gross proceeds of $90 million from the offering. The offering was upsized from the initial plan of an offering worth $75 million. The shares will commence trading on the Nasdaq under the ticker symbol CALT.See more from Benzinga * The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic * Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics * The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer

    PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced a Phase 2 clinical trial to evaluate its lead immunotherapy product, PDS0101, in combination with standard of care chemoradiotherapy for treatment of locally advanced cervical cancer. The clinical trial will be conducted at The University of Texas MD Anderson Cancer Center and the Lyndon B. Johnson Hospital in Houston by Ann H. Klopp, M.D., Ph.D., Associate Professor of Radiation Oncology and Olsi Gjyshi, M.D., Ph.D. The clinical trial will investigate the safety and anti-tumor efficacy of the PDS0101-chemoradiation combination, and their correlation with critical biomarkers of an immune response in patients with locally advanced cervical cancer.

  • ACCESSWIRE

    47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

    NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from around ...

  • GlobeNewswire

    PDS Biotechnology to Present at the 2020 Virtual Investor Summit

    PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, is scheduled to present  at the 2020 Virtual Investor Summit being held on June 9-12, 2020. PDS Biotech’s management team will also be available for one-on-one conference calls with investors who are registered to attend the event. Alternatively, interested investors may contact Tram Bui of The Ruth Group at tbui@theruthgroup.com to schedule a call.

  • GlobeNewswire

    PDS Biotechnology Announces Publication at American Society of Clinical Oncology (ASCO) 2020

    PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the publication of its abstract on preclinical studies of PDS0102 at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program being held May 29-31, 2020. Versamune® is a proprietary T-cell activating platform technology designed to train the immune system to detect and attack cancer cells. The published data demonstrate that Versamune®, when combined with the proprietary T-cell receptor gamma alternate reading frame protein (TARP), has the ability to activate a powerful killer T-cell response which specifically recognizes and attacks TARP-expressing cancer cells.

  • GlobeNewswire

    PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update

    FLORHAM PARK, N.J., May 13, 2020 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious.

  • GlobeNewswire

    PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2020 Financial Results

    FLORHAM PARK, N.J., May 04, 2020 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious.

  • The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
    Benzinga

    The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) • Bio-Rad Laboratories, Inc. Class A Common Stock(NYSE: BIO) • Capricor Therapeutics Inc (NASDAQ: CAPR)( reacted to data that showed a 100% survival rate in COVID-19 patients treated with its CAP-1002 cell therapy) • Cue Biopharma Inc (NASDAQ: CUE) • DexCom, Inc. (NASDAQ: DXCM)(reacted to its quarterly results) • Erytech Pharma SA (NASDAQ: ERYP)(announced Fast Track Designation from the FDA for its cancer drug in pancreatic cancer) • GenMark Diagnostics, Inc (NASDAQ: GNMK) • I-Mab ADR (NASDAQ: IMAB) • Immunomedics, Inc. (NASDAQ: IMMU) • Keros Therapeutics Inc (NASDAQ: KROS) • Masimo Corporation (NASDAQ: MASI)(announced solid first-quarter results) • Mersana Therapeutics Inc (NASDAQ: MRSN) • Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) • Zynex Inc. (NASDAQ: ZYXI)(announced its first-quarter results)None of the Nasdaq- or NYSE-listed biotech/medical device/diagnostics company hit 52-week lows Wednesday.Stocks In Focus Marker's Leukemia Drug Candidate Gets Orphan Drug Designation Marker Therapeutics, Inc. (NASDAQ: MRKR) said the FDA accorded Orphan Drug Designation to MT-401, its multi-tumor-associated antigen-specific T cell product for the treatment of patients with acute myeloid leukemia following allogenic stem cell transplant.In after-hours trading, the stock rallied 23.79% to $2.81.Evotec Unit to Work With Ology to Develop Antibodies Against Coronavirus German biopharma Evotec SE (OTC: EVOTF) said its Seattle-based subsidiary Just-Evotec Biologics has entered into a partnership with Ology Bioservices for the evaluation and analytical characterisation of antibodies against SARS-CoV-2 - the virus that causes COVID-19.The company noted this work was based on a contract awarded to Ology by the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies to develop, and manufacture monoclonal antibodies for the treatment and prevention of infections with SARS-CoV-2FDA Approves an Expanded Indication For GlaxoSmithKline's Ovarian Cancer Drug GlaxoSmithKline plc (NYSE: GSK) announced FDA approval for its sNDA for Zejula as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker statusThe stock was up 1.51% to $42.48 in pre-market trading.PDS Biotech Announces Expansion to Cancer Drug Collaboration With NCI PDS Biotechnology Corp (NASDAQ: PDSB) announced an expansion of its previously announced Cooperative Research and Development Agreement with the National Cancer Institute to include studies of PDS0103, a Versamune-based product incorporating novel mucin-1 epitopes developed by the NCI.NCI is already evaluating PDS0101 in combination with two separate immune-modulating agents - NHS-IL12 and M7824 - in a phase 2 clinical trial in advanced HPV-associated cancers.The stock was adding 2.61% to 97 cents in pre-market trading.BeiGene, IGM, Atreca To Work On Coronavirus Treatment Atreca Inc (NASDAQ: BCEL), Beigene Ltd (NASDAQ: BGNE) and IGM Biosciences Inc (NASDAQ: IGMS) announced plans to collaborate to develop novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The companies said work will commence immediately, with the financial and other terms to be finalized in the future.In pre-market trading, BeiGene was edging up 0.42% to $162.30 and Atreca was advancing 3.57% to $18.Offerings NeoGenomics, Inc. (NASDAQ: NEO) priced its proposed underwritten public offerings of 4.4 million newly issued shares at $28.50 per share. The company also said it's offering $175 million in aggregate principal amount of its 1.25% convertible senior notes due 2025.The company also said underwriters of the common stock offering are also offering 1.065 million worth of shares of NeoGenomics borrowed from third parties.View more earnings on IBBThe stock slid 4.90% to $29.50 in after-hours trading.Syndax Pharmaceuticals Inc (NASDAQ: SNDX) announced plans to offer shares of its common stock in an underwritten public offering. All the shares are being offered by the company.In pre-market trading, the stock was adding 0.27% to $18.75.Earnings Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported first-quarter revenues of $1.52 million, up from $858.44 million in the year-ago quarter. On a non-GAAP basis, earnings per share, or EPS, climbed from $1.14 to $2.56, ahead of the $1.84 per share consensus estimate. The company upwardly revised its full-year net product revenue guidance.The stock was adding 2.97% to $258.50 in pre-market trading.Hologic, Inc.'s (NASDAQ: HOLX) second-quarter revenues fell 7.6% to $756.1 million, primarily reflecting Cynosure divestiture. The company reported non-GAAP EPS of 57 cents, in line with the consensus. The company withdrew its guidance for the second quarter and full year.Separately, the company said it plans to launch a new Aptima molecular assay to detect the SARS-CoV-2 virus that will run on its market-leading Panther system. The company expects to begin distributing a Research Use Only version of its test next week. It also plans to apply for Emergency Use Authorization with the FDA next week and register a CE Mark for diagnostic use in Europe later in May.In pre-market trading, the stock was jumping 9.07% to $53.39.Amarin Corporation plc's (NASDAQ: AMRN) first-quarter revenues climbed 112% to $155 million. The net loss per share on a non-GAAP basis narrowed from 5 cents to 3 cents. The results trumped the consensus that called for a loss of 7 cents per share on revenues of $137.43 million.Regarding the ANDA litigation, the company said hearing could happen in the third quarter or early fourth quarter, with a ruling likely in 2020 or in early 2021.Amarin said it believes that it has a strong basis for appeal, which will be set out in its opening brief proposed for filing on May 12th.In pre-market trading, Amarin shares were rallying 3.75% to $8.57.On The Radar Earnings • Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the market open) • ABIOMED, Inc. (NASDAQ: ABMD) (before the market open) • Baxter International Inc (NYSE: BAX) (before the market open) • BIO-TECHNE Corp (NASDAQ: TECH) (before the market open) • Genocea Biosciences Inc (NASDAQ: GNCA) (before the market open) • Novocure Ltd (NASDAQ: NVCR) (before the market open) • Syneos Health Inc (NASDAQ: SYNH) (before the market open) • PRA Health Sciences Inc (NASDAQ: PRAH) (before the market open) • Lantheus Holdings Inc (NASDAQ: LNTH) (before the market open) • Iradimed Corp (NASDAQ: IRMD) (before the market open) • Concert Pharmaceuticals Inc (NASDAQ: CNCE) (before the market open) • Amgen, Inc. (NASDAQ: AMGN) (after the close) • Emergent Biosolutions Inc (NYSE: EBS) (after the close) • Insmed Incorporated (NASDAQ: INSM) (after the close) • Gilead Sciences, Inc. (NASDAQ: GILD) (after the close) • Seattle Genetics, Inc. (NASDAQ: SGEN) (after the close) • Natus Medical Inc (NASDAQ: NTUS) (after the close) • Illumina, Inc. (NASDAQ: ILMN) (after the close) • PTC Therapeutics, Inc. (NASDAQ: PTCT) (after the close) • LeMaitre Vascular Inc (NASDAQ: LMAT) (after the close) • ResMed Inc. (NYSE: RMD) (after the close) • Viking Therapeutics Inc (NASDAQ: VKTX) (after the close) • Silk Road Medical Inc (NASDAQ: SILK) (after the close) • Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the close) • CareDx Inc (NASDAQ: CDNA) (after the close) • Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close) • Ekso Bionics Holdings Inc (NASDAQ: EKSO) (after the close)See more from Benzinga * The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda * The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update * The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Product

    PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced an expansion of its previously announced Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to include studies of PDS0103, a Versamune®-based product incorporating novel mucin-1 (MUC1) epitopes developed by the NCI. This expansion adds to the NCI’s ongoing evaluation of PDS0101 in combination with two separate immune-modulating agents, NHS-IL12 and M7824, which will be evaluated in a phase 2 clinical trial in advanced HPV-associated cancers (NCT04287868). Under the expanded CRADA, PDS Biotech will collaborate with the NCI Center for Cancer Research’s Genitourinary Malignancies Branch (GMB) and the Laboratory of Tumor Immunology and Biology (LTIB) to conduct preclinical studies of PDS0103, and potentially human clinical studies in combination with other therapeutic agents.

  • GlobeNewswire

    PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial

    PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced an expanded infectious disease pandemic development program, including novel vaccines for COVID-19 and universal influenza, in addition to its previously announced tuberculosis development collaboration with Farmacore Biotechnology. The Company also announced that initiation of its multi-center Phase 2 VERSATILE-002 trial for PDS0101 in advanced/metastatic head and neck cancer has been delayed due to the severe adverse impact on clinical trial operations from the COVID-19 pandemic.

  • GlobeNewswire

    PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors

    PDS Biotechnology Corporation (“PDS Biotechnology”) (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune® today announced that it has appointed Ilian Iliev, Ph.D. to its Board of Directors. “Together, we will help guide PDS Biotech through its near and long-term milestones as we advance our programs in infectious disease and immuno-oncology with leading research institutions and pharmaceutical companies.”

  • GlobeNewswire

    PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update

    PRINCETON, N.J., March 27, 2020 -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies.

  • GlobeNewswire

    PDS Biotechnology Announces Resignation of Andrew Saik as CFO

    PRINCETON, N.J., March 23, 2020 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s.

  • GlobeNewswire

    PDS Biotechnology Expands Patent Portfolio for its Novel Versamune® Platform

    PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has been granted U.S. Patent No. 15/702,063 titled “Stimulation of an Immune Response by Enantiomers of Cationic Lipids” by the United States Patent and Trademark Office (USPTO). "As we advance our lead program, PDS0101 towards three Phase 2 studies this year with leaders in the field of immuno-oncology, we believe that our Versamune® platform holds the potential to significantly improve clinical outcomes for patients.”

  • GlobeNewswire

    PDS Biotechnology Announces Commencement of Work Under a Pre-Clinical Collaboration with Farmacore Biotechnology for Tuberculosis

    PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced commencement of work under an Amended and Restated Material Transfer Agreement with Farmacore Biotechnology, experts in infectious diseases, to develop a novel tuberculosis (TB) immunotherapy based on Farmacore’s proprietary TB antigens and PDS Bio’s Versamune® platform technology. The prior Material Transfer Agreement under which preliminary work commenced was Amended and Restated in December 2019 due to promising early pre-clinical results and to progress this next phase of development.

  • GlobeNewswire

    PDS Biotechnology Appoints Kamil Ali-Jackson, Esq. to Board of Directors

    PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has appointed Kamil Ali-Jackson, Esq. Ms. Ali-Jackson will be a member of the Board’s audit committee.

  • GlobeNewswire

    PDS Biotechnology to Present at Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

    PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer and Dr. Lauren Wood, Chief Medical Officer are scheduled to participate in Noble Capital Markets' 16th Annual Small & Microcap Investor Conference being held on February 16-18, 2020 at the Seminole Hard Rock Hotel & Casino in Hollywood, FL. A live webcast of the corporate presentation may be accessed on the Company's website at pdsbiotech.com or directly here.

  • GlobeNewswire

    PDS Biotechnology Corporation Announces Closing of Public Offering

    PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 9,230,770 shares of common stock at a public offering price of $1.30 per share. The net proceeds to PDS Biotechnology from this offering, after deducting underwriting discounts, commissions were approximately $11 million and does not include other offering expenses. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website, located at www.sec.gov.

  • Benzinga

    The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...

  • GlobeNewswire

    PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock

    PDS Biotechnology Corporation (“PDS Biotechnology”) (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on PDS Biotechnology’s proprietary Versamune® T-cell activating technology, today announced the pricing of an underwritten public offering consisting of 9,230,770 shares of common stock at a price to the public of $1.30 per share. The gross proceeds to PDS Biotechnology from this offering are expected to be approximately $12,000,000, before deducting underwriting discounts, commissions and other offering expenses.

  • GlobeNewswire

    PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference

    PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, is scheduled to present at the 2020 BIO CEO & Investor Conference being held on February 10-11, 2020 at the Marriott Marquis in New York, NY. A live webcast of the presentation may be accessed on the Company's website at pdsbiotech.com or directly here. PDS Biotech is a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology platform.